DexTech Medical AB (XSAT:DEX) EBITDA Margin %: 0.00% (As of Mar. 2026)


XSAT:DEX DexTech Medical AB XSAT:DEX
32 GF Score
Price kr10.30
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB EBITDA Margin %?

DexTech Medical AB XSAT:DEX 32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, DexTech Medical AB ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. DexTech Medical AB's EBITDA for the three months ended in Mar. 2026 was kr-1.75 Mil. DexTech Medical AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, DexTech Medical AB's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

DexTech Medical AB  (XSAT:DEX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

DexTech Medical AB EBITDA Margin % Related Terms

DexTech Medical AB EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB EBITDA Margin % Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSAT:DEX vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, DexTech Medical AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DexTech Medical AB EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's EBITDA Margin % falls into.


XSAT:DEX
32GF Score
DexTech Medical AB XSAT:DEX
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

DexTech Medical AB's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-1.105/0
= %

DexTech Medical AB's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.748/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
DexTech Medical AB (XSAT:DEX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DexTech Medical AB and its competitors. According to the industry distribution chart, DexTech Medical AB ranks #999999 out of 944 companies in the Biotechnology industry.
Is DexTech Medical AB's EBITDA Margin % too high?
DexTech Medical AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, DexTech Medical AB ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DexTech Medical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #999999 out of 944 companies for EBITDA Margin %. This places DexTech Medical AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DexTech Medical AB and its competitors. DexTech Medical AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. DexTech Medical AB's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
32GF Score

Get the complete analysis for XSAT:DEX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.30
Price